As reported in The Lancet Child and Adolescent Health 2021, a cross-sectional study from the IMVASK cohort enrolled and investigated human immunodeficiency virus (HIV)-infected children who were previously treated with antiretroviral therapy (ART) for at least 2 years, and were compared against children of the same age without HIV.
Human immunodeficiency virus (HIV) has been transformed into a chronic disease to the successful introduction of antiretroviral therapy (ART), and people living with HIV (PWH) now experience morbidity from other chronic conditions, such as kidney, liver, and heart disease.
The incidence of anal cancer has been increasing over the past decade, but currently still constitutes 0.5% of all cancer diagnoses in the United States. When the cancer has metastasised, prognosis remains poor, with relative 5-year survival rates of approximately 30%. The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU). However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted. The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.